Hormonal
Tirzepatide produces substantial, dose-dependent weight loss in non-diabetic adults with obesity, with maximum tolerated doses achieving mean body weight reductions of approximately 20.9% compared to placebo.
If you have obesity and do not have diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss. The medication works by mimicking hormones that regulate appetite and metabolism. Higher doses (up to the maximum tolerated dose) yield greater weight loss, with some patients losing over 20% of their body weight. While gastrointestinal side effects like nausea are common, they do not appear to increase the risk of serious health events compared to a placebo, making it a viable option for chronic weight management.
Tirzepatide significantly reduced the percentage body weight compared to placebo (mean difference -16.54%; 95% CI -17.48 to -15.59; p < 0.00001)... Participants who escalated to their MTD (10 or 15 mg) experienced the greatest reduction, with a pooled MD of -20.90% (95% CI -23.29 to -18.51%; p < 0.00001).
Why this rating
Based on a systematic review and meta-analysis of 4 high-quality RCTs with over 3,500 participants.
Source
Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Alousious Kasagga et al. · Cureus · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →